Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neobianacid vs Omeprazole for Heartburn and Epigastric Pain
NCT03238534Phase 4Completed
- Sponsor
- Aboca
- Start
- Sep 2017
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Aboca. Primary endpoint: Heartburn or epigastric pain severity through treatment (Day-1 to Day13). Started Sep 2017; status: completed.
02
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03238534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238534.